Capital Impact Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Capital Impact Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,136	Closed	-$489K	–	169
2023 Q2	$489K	Buy	25,136 +11,529	+85%	+$274K	0.54%	91
2023 Q1	$386K	Buy	13,607 +903	+7%	+$26.8K	0.47%	97
2022 Q4	$371K	Hold	12,704	–	–	0.36%	120
2022 Q3	$465K	Buy	12,704 +976	+8%	+$35.8K	0.46%	86
2022 Q2	$521K	Sell	11,728 -4,190	-26%	-$192K	0.48%	86
2022 Q1	$788K	Sell	15,918 -3,358	-17%	-$161K	0.57%	71
2021 Q4	$982K	Hold	19,276	–	–	0.68%	55
2021 Q3	$1.07M	Hold	19,276	–	–	0.43%	97
2021 Q2	$825K	Sell	19,276 -16,539	-46%	-$682K	0.27%	118
2021 Q1	$1.5M	Hold	35,815	–	–	0.52%	72
2020 Q4	$1.67M	Hold	35,815	–	–	0.41%	93
2020 Q3	$1.52M	Hold	35,815	–	–	0.45%	90
2020 Q2	$1.72M	Hold	35,815	–	–	0.57%	84
2020 Q1	$1.65M	Buy	35,815 +2,090	+6%	+$105K	0.69%	67
2019 Q4	$2.03M	Hold	33,725	–	–	0.71%	77
2019 Q3	$1.9M	Sell	33,725 -1,424	-4%	-$80.1K	0.73%	79
2019 Q2	$1.93M	Buy	35,149 +1,210	+4%	+$63.1K	0.71%	60
2019 Q1	$1.33M	Hold	33,939	–	–	0.59%	98
2018 Q4	$1.33M	Buy	33,939 +9,855	+41%	+$508K	0.57%	101
2018 Q3	$1.66M	Hold	24,084	–	–	0.57%	99
2018 Q2	$1.83M	Sell	24,084 -2,233	-8%	-$140K	0.68%	65
2018 Q1	$1.39M	Buy	+26,317	New	+$1.53M	0.57%	92

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Impact Advisors's EGRX Position: Q3 2023 in Review

Capital Impact Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 25,136 shares — an estimated $489K sold.

Capital Impact Advisors first reported a position in EGRX in Q1 2018 and held it in 22 quarters. The position peaked at $2.03M in Q4 2019. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

Capital Impact Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Capital Impact Advisors sold 25,136 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $489K.
Capital Impact Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 22 quarters.
Capital Impact Advisors's Eagle Pharmaceuticals, Inc. position peaked at $2.03M in Q4 2019.
107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.